Catch up on the stories that caught the attention of our readers here:
Repeat observations for Teva’s facility resulted in the US Food and Drug Administration issuing a warning letter, citing ‘inadequate oversight and control by executive management’.
It was revealed that the Anglo-Swedish company would cut a number of positions from its Macclesfield, UK, site by 2020, after GMB Union stated it had been involved in negotiations.
Pfizer exercised an option from a previous agreement with AnTolRx to develop and license an immune tolerance therapy for type 1 diabetes.
A study carried out by MIT researchers found that 93% of medications contain excipients with the potential to cause an allergic reaction, resulting in a call for greater allergy information.
Camber and Macleods voluntarily recalled lots of losartan tablets, after trace amounts of a possible carcinogen was found in an API ingredient manufactured at the same third-party facility.